Unmanipulated HLA‐mismatched/haploidentical peripheral blood stem cell transplantation for high‐risk hematologic malignancies

BACKGROUND: Haploidentical hematopoietic stem cell transplantation (HSCT) has been increasingly applied in high‐risk hematologic patients due to the absence of HLA‐matched donors. The aim of this study was to investigate the efficacy and safety of unmanipulated haploidentical allogeneic peripheral blood stem cells transplantation (PBSCT) for hematologic malignancies.

[1]  J. Perkins,et al.  ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  J. Kanda,et al.  Haploidentical Transplantation for Leukemia , 2010, Current oncology reports.

[3]  W. Han,et al.  The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis , 2010, Bone Marrow Transplantation.

[4]  Xiao-jun Huang,et al.  HLA-haploidentical stem cell transplantation for hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  Brit B. Turnbull,et al.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. , 2009, Blood.

[6]  Yu-Hong Chen,et al.  Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  Yu-Hong Chen,et al.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  K. van Besien,et al.  Reduced-intensity and nonmyeloablative conditioning regimens. , 2009, Cancer treatment and research.

[9]  Xiao-jun Huang,et al.  Current status of haploidentical stem cell transplantation for leukemia , 2008, Journal of hematology & oncology.

[10]  Arnon Nagler,et al.  A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. , 2008, Blood.

[11]  F. Aversa,et al.  Unmanipulated or CD34 selected haplotype mismatched transplants , 2008, Current opinion in hematology.

[12]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  F. Aversa,et al.  Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States , 2008, Bone Marrow Transplantation.

[14]  I. Kawase,et al.  Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. , 2008, Experimental hematology.

[15]  K. Sullivan.  Graft‐vs.‐Host Disease , 2007 .

[16]  A. Baruchel,et al.  Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies , 2007, Bone Marrow Transplantation.

[17]  K. Sullivan,et al.  Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Martelli,et al.  Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option. , 2007, Current stem cell research & therapy.

[19]  I. Kawase,et al.  Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  R. Krance,et al.  Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. , 2006, Blood.

[21]  D. Maloney,et al.  A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation , 2006, Bone Marrow Transplantation.

[22]  Yu-Hong Chen,et al.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.

[23]  Flora Zavala,et al.  Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance1 , 2005, The Journal of Immunology.

[24]  R. Negrin,et al.  Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. , 2005, Blood.

[25]  R. Egeler,et al.  Graft dysfunction and delayed immune reconstitution following haploidentical peripheral blood hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[26]  S. Yamasaki,et al.  Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies , 2004, Bone Marrow Transplantation.

[27]  S. Chevret,et al.  Results of unrelated umbilical cord blood hematopoietic stem cell transplantation. , 2001, Reviews in clinical and experimental hematology.

[28]  C. Bredeson,et al.  Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose , 2001, Bone Marrow Transplantation.

[29]  T. Lion,et al.  Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment , 1999, Leukemia.

[30]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[31]  M. Bishop,et al.  Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. , 1996, Bone marrow transplantation.

[32]  J. O’Shaughnessy,et al.  Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. , 1995, Experimental hematology.

[33]  R. Storb,et al.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. , 1990, Human immunology.